First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors
ConclusionsWith C4 cut-off and prophylactic bile acid sequestrant implementation, INCB062079 demonstrated a manageable safety profile and evidence of target inhibition. In view of the rarity ofFGF19/FGFR4 alterations and slow patient accrual, the study was terminated before establishing an MTD. (Source: Targeted Oncology)
Source: Targeted Oncology - February 14, 2023 Category: Cancer & Oncology Source Type: research
Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies
(Source: Targeted Oncology)
Source: Targeted Oncology - February 8, 2023 Category: Cancer & Oncology Source Type: research
Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective
AbstractBiliary tract cancers (BTCs) are a heterogeneous group of tumors that are rare in Western countries and have a poor prognosis. Three subgroups are defined by their anatomical location (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma and gallbladder carcinoma) and exhibit distinct clinical, molecular, and epidemiologic characteristics. Most patients are diagnosed at an advanced disease stage and are not eligible for curative-intent resection. In addition to first- and second-line chemotherapies (CisGem and FOLFOX, respectively), biologic therapies are now available that target specific genomic alter...
Source: Targeted Oncology - February 6, 2023 Category: Cancer & Oncology Source Type: research
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients
ConclusionThe present analysis constitutes the first evidence of a negative prognostic impact of IDH1 mutations in a cohort of patients treated after progression on first-line therapies in contrast to IDH1 inhibitors. (Source: Targeted Oncology)
Source: Targeted Oncology - January 23, 2023 Category: Cancer & Oncology Source Type: research
Relugolix: A Review in Advanced Prostate Cancer
AbstractRelugolix (Orgovyx®), an orally active nonpeptide gonadotropin-releasing hormone (GnRH) receptor antagonist that provides rapid testosterone suppression, is indicated in the USA for the treatment of advanced prostate cancer and in the EU for advanced hormone-sensitive prostate cancer. In the pivotal phase III HERO trial in men with advanced prostate cancer, once-daily oral relugolix (with a loading dose on day 1) led to a sustained castration rate over 48 weeks of treatment of> 90%, a rate that was non-inferior to that provided by intramuscular leuprolide depot every 3 months (with an exploratory analysis...
Source: Targeted Oncology - January 18, 2023 Category: Cancer & Oncology Source Type: research
Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies
AbstractCentral nervous system (CNS) metastases are common in non-small-cell lung cancer (NSCLC) and associated with poor prognosis and high disease burden. Effective options are needed to treat CNS metastases, and delay or prevent their formation. For epidermal growth factor receptor mutation-positive (EGFRm) advanced NSCLC and brain metastases, upfront EGFR-tyrosine kinase inhibitors (TKIs) are recommended by the joint European Association of Neuro-Oncology –European Society for Medical Oncology and experts. While early-generation EGFR-TKIs have limited CNS efficacy, the third-generation, irreversible, EGFR-TKI osimert...
Source: Targeted Oncology - January 18, 2023 Category: Cancer & Oncology Source Type: research
Selinexor –Bortezomib–Dexamethasone: A Review in Previously Treated Multiple Myeloma
AbstractSelinexor [Nexpovio® (EU); Xpovio® (USA)] is a first-in-class, selective exportin-1 inhibitor. Oral selinexor once weekly in combination with subcutaneous bortezomib once weekly and oral dexamethasone twice weekly (selinexor –bortezomib–dexamethasone) is approved in the EU and USA for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. In the open-label, randomized, phase 3 BOSTON trial, this regimen significantly prolonged progression-free survival (PFS) compared with the standard bortezomib–dexamethasone regimen in patients with previously treated multiple m...
Source: Targeted Oncology - January 9, 2023 Category: Cancer & Oncology Source Type: research
Emerging Biomarkers in Immune Oncology to Guide Lung Cancer Management
AbstractOver the last decade, the use of targeted therapies and immune therapies led to drastic changes in the management lung cancer and translated to improved survival outcomes. This growing arsenal of therapies available for the management of non-small cell lung cancer added more complexity to treatment decisions. The genomic profiling of tumors and the molecular characterization of the tumor microenvironment gradually became essential steps in exploring and identifying markers that can enhance patient selection to facilitate treatment personalization and narrow down therapy options. The advent of innovative diagnostic ...
Source: Targeted Oncology - December 29, 2022 Category: Cancer & Oncology Source Type: research
Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma
ConclusionsThe development of immune-related adverse events was positively associated with the outcome of patients with advanced renal cell carcinoma treated with IO-IO combination therapy; no such correlation was observed for IO-TKI combination therapy. (Source: Targeted Oncology)
Source: Targeted Oncology - December 26, 2022 Category: Cancer & Oncology Source Type: research
Current and Future Perspectives of Health-Related Quality of Life in Resectable EGFR-Mutated Non-Small Cell Lung Cancer: A Podcast
(Source: Targeted Oncology)
Source: Targeted Oncology - December 19, 2022 Category: Cancer & Oncology Source Type: research
Prognostic Significance of the Severity of Immune-Related Adverse Events in Advanced Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Real-World Data Analysis
ConclusionsThe development of grade ≥ 3 irAEs was affected by comorbidities and associated with improved PFS compared with those without irAEs. Our findings identified the real-world epidemiology, risk factors, and prognostic significance of irAEs, which may guide treatment decisions of PD-1/PD-L1 inhibitors. (Source: Targeted Oncology)
Source: Targeted Oncology - December 14, 2022 Category: Cancer & Oncology Source Type: research
Recent Evidence-Based Clinical Guide for the Use of Dinutuximab Beta in Pediatric Patients with Neuroblastoma
The objective of this article was to update the clinical guide to management with dinutuximab beta of children with neuroblastoma based on the most recent published evidence and our own experience in clinical practice. (Source: Targeted Oncology)
Source: Targeted Oncology - December 12, 2022 Category: Cancer & Oncology Source Type: research
Impact of KRAS Mutations on Clinical Outcomes of Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Receiving Anti-PD-1/PD-L1 Therapy
ConclusionOur data confirmed that KRAS mutational status is not associated with survival and response outcomes in advanced non-squamous NSCLC patients treated with immunotherapy alone or combined with chemotherapy. (Source: Targeted Oncology)
Source: Targeted Oncology - December 8, 2022 Category: Cancer & Oncology Source Type: research
Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases
ConclusionsRelugolix administered at approved standard doses concurrently with apalutamide was effective in maintaining castrate testosterone levels in HR-LPC without new safety signals.Trial Registration Number and DateNCT04523207, 21 August 2020.Graphical abstract (Source: Targeted Oncology)
Source: Targeted Oncology - December 6, 2022 Category: Cancer & Oncology Source Type: research
Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors
ConclusionsThe safety profile of single-agent glesatinib was acceptable. SDD 750 mg twice daily was selected as the preferred glesatinib formulation and dose based on clinical activity, safety, and PK data. Observations from this study led to initiation of a phase II study of glesatinib in patients with NSCLC stratified by type ofMET alteration (NCT02544633).Clinical Trials RegistrationClinicalTrials.gov NCT00697632; June 2008. (Source: Targeted Oncology)
Source: Targeted Oncology - December 2, 2022 Category: Cancer & Oncology Source Type: research
